These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 30934067

  • 1. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
    Dugdale CM, Ciaranello AL, Bekker LG, Stern ME, Myer L, Wood R, Sax PE, Abrams EJ, Freedberg KA, Walensky RP.
    Ann Intern Med; 2019 May 07; 170(9):614-625. PubMed ID: 30934067
    [Abstract] [Full Text] [Related]

  • 2. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
    Davey S, Ajibola G, Maswabi K, Sakoi M, Bennett K, Hughes MD, Isaacson A, Diseko M, Zash R, Batlang O, Moyo S, Lockman S, Lichterfeld M, Kuritzkes DR, Makhema J, Shapiro R.
    J Acquir Immune Defic Syndr; 2020 Jul 01; 84(3):235-241. PubMed ID: 32195745
    [Abstract] [Full Text] [Related]

  • 3. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, Wensing A, Lundgren JD, Pillay D, Mellors J, Cambiano V, Jahn A, Apollo T, Mugurungi O, Ripin D, Da Silva J, Raizes E, Ford N, Siberry GK, Gupta RK, Barnabas R, Revill P, Cohn J, Calmy A, Bertagnolio S.
    Lancet HIV; 2020 Mar 01; 7(3):e193-e200. PubMed ID: 32035041
    [Abstract] [Full Text] [Related]

  • 4. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K, Malaba TR, Nakibuka J, Papamichael C, Colbers A, Byrne K, Seden K, Hodel EM, Chen T, Twimukye A, Byamugisha J, Reynolds H, Watson V, Burger D, Wang D, Waitt C, Taegtmeyer M, Orrell C, Lamorde M, Myer L, Khoo S, DolPHIN-2 Study Group.
    Lancet HIV; 2020 May 01; 7(5):e332-e339. PubMed ID: 32386721
    [Abstract] [Full Text] [Related]

  • 5. Attrition from care and its predictors among women exposed to dolutegravir- and efavirenz-based first-line antiretroviral therapy in Ethiopia: a before-and-after study.
    Facha W, Tadesse T, Wolka E, Astatkie A.
    Front Public Health; 2024 May 01; 12():1385441. PubMed ID: 39015389
    [Abstract] [Full Text] [Related]

  • 6. Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.
    Facha W, Tadesse T, Wolka E, Astatkie A.
    PLoS One; 2024 May 01; 19(6):e0305331. PubMed ID: 38857273
    [Abstract] [Full Text] [Related]

  • 7. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, Kaboggoza J, Sihlangu M, Coombs JA, Malaba T, Byamugisha J, Amara A, Gini J, Else L, Heiburg C, Hodel EM, Reynolds H, Mehta U, Byakika-Kibwika P, Hill A, Myer L, Lamorde M, Khoo S.
    PLoS Med; 2019 Sep 01; 16(9):e1002895. PubMed ID: 31539371
    [Abstract] [Full Text] [Related]

  • 8. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, Gaolethe T, Petlo C, Lockman S, Holmes LB, Makhema J, Shapiro RL.
    Lancet Glob Health; 2018 Jul 01; 6(7):e804-e810. PubMed ID: 29880310
    [Abstract] [Full Text] [Related]

  • 9. The safety of a dolutegravir (DTG)-based antiretroviral treatment (ART) regimen for pregnancy and birth outcomes in Ethiopia: evidence from multicenter cohort study.
    Gedefaw A, Tadesse BT, Berhan Y, Makonnen E, Vella S, Aklillu E.
    BMC Infect Dis; 2024 Sep 02; 24(1):901. PubMed ID: 39223552
    [Abstract] [Full Text] [Related]

  • 10. Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study.
    Nightingale S, Dreyer AJ, Thomas KGF, van Zyl G, Decloedt E, Naude PJW, Orrell C, Sinxadi P, Winston A, Khoo S, Joska JA.
    Lancet HIV; 2024 Oct 02; 11(10):e680-e689. PubMed ID: 39284338
    [Abstract] [Full Text] [Related]

  • 11. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
    Ochanda PN, Lamorde M, Kintu K, Wang D, Chen T, Malaba T, Myer L, Waitt C, Reynolds H, Khoo S.
    AIDS Res Ther; 2022 Jun 07; 19(1):24. PubMed ID: 35672853
    [Abstract] [Full Text] [Related]

  • 12. Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.
    Hermans LE, Nijhuis M, Tempelman HA, Houts T, Schuurman R, Burger DM, Wensing AMJ, ter Heine R.
    J Acquir Immune Defic Syndr; 2021 Aug 01; 87(4):1072-1078. PubMed ID: 34153013
    [Abstract] [Full Text] [Related]

  • 13. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
    Pereira GFM, Kim A, Jalil EM, Fernandes Fonseca F, Shepherd BE, Veloso VG, Rick F, Ribeiro R, Pimenta MC, Beber A, Corrêa RG, Lima R, Maruri F, McGowan CC, Schwartz Benzaken A, Grinsztejn B, Castilho JL, National Cohort Study of Dolutegravir and Pregnancy Outcomes in Brazil.
    Lancet HIV; 2021 Jan 01; 8(1):e33-e41. PubMed ID: 33387477
    [Abstract] [Full Text] [Related]

  • 14. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.
    Shamu T, Egger M, Mudzviti T, Chimbetete C, Manasa J, Anderegg N.
    J Int AIDS Soc; 2024 Feb 01; 27(2):e26216. PubMed ID: 38332525
    [Abstract] [Full Text] [Related]

  • 15. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N, McCann K, Norris S, Chersich M, Maartens G, Lalla-Edward S, Vos A, Clayden P, Abrams E, Arulappan N, Hill A.
    Lancet HIV; 2020 Oct 01; 7(10):e666-e676. PubMed ID: 33010240
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative Effects of Efavirenz and Dolutegravir on Metabolomic and Inflammatory Profiles, and Platelet Activation of People Living with HIV: A Pilot Study.
    Roux CG, Mason S, du Toit LDV, Nel JG, Rossouw TM, Steel HC.
    Viruses; 2024 Sep 14; 16(9):. PubMed ID: 39339938
    [Abstract] [Full Text] [Related]

  • 18. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
    Shamu T, Egger M, Mudzviti T, Chimbetete C, Manasa J, Anderegg N.
    PLoS One; 2024 Sep 14; 19(2):e0293162. PubMed ID: 38394297
    [Abstract] [Full Text] [Related]

  • 19. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
    Malaba TR, Nakatudde I, Kintu K, Colbers A, Chen T, Reynolds H, Read L, Read J, Stemmet LA, Mrubata M, Byrne K, Seden K, Twimukye A, Theunissen H, Hodel EM, Chiong J, Hu NC, Burger D, Wang D, Byamugisha J, Alhassan Y, Bokako S, Waitt C, Taegtmeyer M, Orrell C, Lamorde M, Myer L, Khoo S, DolPHIN-2 Study Group.
    Lancet HIV; 2022 Aug 14; 9(8):e534-e543. PubMed ID: 35905752
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, Popoff E, Bansback N, Nsanzimana S, Thorlund K, Mills EJ.
    Lancet HIV; 2016 Nov 14; 3(11):e510-e520. PubMed ID: 27658869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.